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Seriniquinone is a natural quinone isolated from a rare marine bacterium of the genus 
Serinicoccus. This secondary metabolite has been shown to have anticancer properties, which has 
raised attention of the scientific community. In this short report, we present the first investigation 
of the gas-phase chemistry fragmentation reactions of seriniquinone in electrospray ionization 
tandem mass spectrometry (ESI-MS/MS), to be further applied in pharmacokinetics and metabolism 
studies. All the proposals herein were supported by computational chemistry.
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Introduction
The research regarding marine natural products have 
been responsible for the discovery of promising compounds 
for the treatment of several diseases, including good 
prototypes for cancer therapy.1 Seriniquinone (SQ, Figure 1), 
a metabolite isolated from a rare marine bacterium of the 
genus Serinicoccus, was recently characterized and evaluated 
for its cytotoxic activity.2 SQ belongs to a class of quinones, 
which is widely present in nature and is considered a target 
scaffold in medicinal chemistry as a gifted class of anticancer 
drugs.2 In vitro screening indicated that SQ is highly 
cytotoxic and selective towards eight out of the nine NCI 
60 melanoma cells lines.2 Biochemical and pharmacological 
assessments demonstrated that SQ specifically targets a skin 
protective antimicrobial peptide, dermcidin,2,3 which has also 
been described as a pro-survival protein in cancer cell lines.4 
SQ is the only known natural product to bind and modulate 
such protein, and recent studies have reported dermcidin to 
be over expressed in some cancers types and linked to a poor 
prognosis of such disease.5,6 In addition, studies have also 
shown that SQ induces autophagocytosis, further leading 
to an efficient elimination of cancer cells through apoptotic 
death.2,7
The advance of new bioactive molecules from natural 
sources to drug development requires preclinical evaluations, 
such as pharmacokinetic profile and metabolism studies, 
to answer basic safety questions concerning biomedical 
use of such compounds.8-10 Serving such a purpose, liquid 
chromatography coupled to electrospray ionization tandem 
mass spectrometry (LC-ESI-MS/MS) is considered to 
be an important analytical technique for identification 
and quantification of the compounds of interest and their 
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metabolites.11 Besides the high sensitivity for analysis 
of small amount of substance in complex matrices, the 
combination of ESI and tandem or sequential mass 
spectrometry (MS/MS or MSn) allows the reaction of a 
precursor ion with a non-reactive collision gas to obtain 
a fragmentation profile for this ion. ESI combined to 
collision-induced dissociation (CID) has already been 
applied for the rapid analysis of quinones, such as lapachol 
and naphthoquinone derivatives.12,13
For an improved application of ESI-MS/MS technique, 
it is important to define the gas phase reactions involved 
and to perform the rationalization of a fragmentation 
pathway of the studied compound.14 Taking into account the 
relevant biological activity and such novel mode of action 
observed for SQ, the goal of this work is to report on the 
fragmentation pathways of SQ. Previous knowledge of the 
fragmentation mechanisms is fundamental to determine 
chemical structures of the biological metabolites of SQ 
and to support better understanding of experimental results 
from in vitro and in vivo preclinical assays.
Experimental
Seriniquinone (SQ) was synthesized as previously 
described,2 affording 10 mg for all ESI-MS/MS analysis. 
Due to a very limited solubility, stock solutions of 
SQ were prepared in DMSO (99.7%, Sigma-Aldrich, 
Brazil). Working solutions of 1 µg mL-1 were prepared 
by dilution in methanol/water (95:5), allowing a final 
DMSO concentration of 0.1%, which has no effect on the 
ionization process.
The experiments were carried out using two Applied 
Biosystems/Sciex instruments: an API 3200 triple 
quadrupole mass spectrometry and a quadrupole ion 
trap mass spectrometry (AB Sciex, Concord, Canada) 
equipped with an electrospray source (TurboIonSpray 
Ion Source). Single compounds were infused at a flow 
rate of 5.0 µL min-1 for tuning compound dependent on 
MS parameters using a model 11 PLUS syringe pump 
(Harvard Apparatus, Holliston, USA) directly connected 
to the interface. Entrance potential (EP) was fixed at 
10 V. Specific compound dependent MS parameters were 
optimized as declustering potential (DP = 70 V), curtain 
gas (CUR = 10 psi), ionspray voltage (IS = 4500 V) and 
nebulizer gas (GS1 = 14 psi). The MS was operated in the 
positive ion and product ion mode.
ESI-MS/MS analyses were performed by CID using 
nitrogen as the collision gas. The protonated molecule was 
selected and fragmented with laboratory-frame energy (Elab) 
in the range of 5 to 60 eV for the precursor ion to achieve 
the energy-resolved fragmentations curves. Data were 
acquired and evaluated using Analyst software.15
Computational quantum calculations were performed 
in order to aid the fragmentation on the quinone derivative. 
Protonated quinonoid compounds exhibit consecutive CO 
eliminations as the major fragmentation pathways, mainly 
when proton takes place at the carbonyl.12,14 Here, the 
gas-phase basicity for protonation on quinone derivative 
was performed using the B3LYP/6-31G(d)16-18 model in 
Gaussian 03 program.19
Fragmentation mechanisms were proposed based on the 
energetic profile for pathways suggested by MS/MS studies. 
All computed energies were obtained in the B3LYP model16 
and minimal energy surface was obtained by analyzing 
positive values for vibrational frequencies.
Results and Discussion
The ESI-MS/MS spectrum of protonated SQ displayed 
product ions of m/z 345, 317, 289, 105 and 77. At normal 
collision energies (around 20 to 25 eV), no fragmentation 
was observed. This initial analysis of the fragmentation 
mechanism of SQ showed a high stability for the protonated 
compound, suggesting high collision energies at the CID 
process (Figure 1a). The major fragmentation occurs after 
35 eV, as observed at Elab plot (Figure 1b).
For the first rationalization, we looked for the 
most favorable protonation site using computational 
chemistry. The gas-phase basicities calculated with the 
Figure 1. (a) Mass spectrum for seriniquinone and (b) Elab experiments 
obtained at QqQ analyzer.
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B3LYP/6-31G(d) model16-18 showed the carbonyl to be 
the most stable protonation site. Protonation at the oxygen 
atom is more stable at 58.8 kcal mol-1, when compared to 
protonation at the sulfur. However, these three possibilities 
for protonation were explored in our studies, as depicted 
in Scheme 1.
The major fragments observed in MS spectra after 
35 eV were m/z 105 and 77. Thus, the pathways were 
suggested on the basis of formation of such ions.
From these results, fragmentation pathways were 
suggested, as displayed on Schemes 1 and 2, considering 
the possibility of the most stable (protonation at the oxygen 
atom) or the most reactive ions (protonated at the sulfur atom) 
to initiate the fragmentation pathways. Formation of the ions 
at m/z 317 and 289 will occur following ring contraction 
(Scheme 1), after collisional activation of m/z 345. The major 
fragment ions at m/z 105 and 77 will also depend on hydrogen 
migration (Scheme 2). In this case, the critical energy for 
this migration and that to eject the acylium fragment ion is 
lower than proposed in Scheme 1.
Detailed analysis of the complete mechanism showed 
the sequential neutral elimination of CO based on 
ring contractions, as previously observed for other 
natural heterocyclic natural compounds produced by 
microorganism.20,21 For the four protonation possibilities 
at the oxygen atoms, an initial tautomeric equilibrium 
Scheme 1. Fragmentation mechanisms for protonated seriniquinone. All 
values are relative Gibbs energies, in kcal mol-1, for fragmentation obtained 
at B3LYP/6-31G(d). Bold values are gas-phase basicity in kcal mol-1.
Scheme 2. Fragmentation mechanisms for protonated seriniquinone. 
All values are relative Gibbs energies, in kcal mol-1, for fragmentation 
obtained at B3LYP/6-31G(d). 
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is necessary before the ring contraction releases CO 
(Scheme 1). In the case of S protonation, the ring contraction 
can occur without any previous steps.14 However, for all 
possibilities, the formation of the most stable ions at 
m/z 105 and 77 requires an unusual five-member ring 
with a triple bond. As shown in Scheme 1, the formation 
of m/z 105 requires 133.7 kcal mol-1 to occur. Regarding 
Scheme 2, the relative energy for formation of m/z 105 
and the transition state were calculated, confirming the 
probability of this reaction. In this case, an alternative 
mechanism of fewer steps must be involved, as suggested 
in Scheme 2. The protonation occurs at the most stable 
carbonyl group and an anchimeric assistance (from the 
oxygen lone in opposition of sulfur atom) will afford the 
intermediated ring opening.14 The alkyne moiety obtained 
in this process can have a long range of hydrogen migration, 
affording a cumulene structure with a terminal carbonyl 
group. Calculation of the transition state was in agreement 
with the proposed pathway (Scheme 2) and, after an 
anchimeric assistance, the oxygen lone pair afforded the 
most stable ions at m/z 105 and 77 (after CO loss).
Conclusions
ESI-MS studies on SQ showed a high stability of the 
protonated compound when submitted to CID conditions. 
ESI-MS/MS analyses of protonated SQ have shown that the 
relative intensity and number of product ions are obtained 
by two competitive pathways, and computational results 
corroborated the ESI-MS/MS. These results will aid in 
the identification of possible SQ products when submitted 
to metabolism studies. Ultimately, data generated in the 
present study has shown the higher stability of the SQ 
moiety. Still, other protocols applying higher collision 
dissociation energies should be employed in further 
LC-MS/MS investigations, including pharmacokinetics 
investigations.
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